BlueSphere Bio

Also RD oncology; TCX-201 2 efforts RD solid tumors

BlueSphere Bio is personalizing T-cell therapies for the treatment of cancer. As every cancer is unique, BlueSphere believes so should therapies. BlueSphere is enabling each patient’s immune system to provide the ability to create their own personal adoptive cell therapy (ACT) to treat their cancer. To achieve this, BlueSphere is using their proprietary technology to harness the specificity of each patient’s T cells for the unique molecular fingerprint of their own cancer. Combined, the technologies screen tumor-resident T cell receptors (TCR) for reactivity to identified neoantigens and create libraries of TCRs and neoantigens to select the best match for ACT. BlueSphere’s lead program, TCX-101, is being tested as a curative therapy for patients with hematologic malignancies.

Jobs: